Abstracts tagged "DMARDs"

Abstract Number: 2460 • 2016 ACR/ARHP Annual Meeting
Predictive Factors of Good Response to Conventional Dmards in Patients with Early Seronegative Rheumatoid Arthritis: Data from the Espoir Cohort
JULIA MARY¹, B Combe², Cédric Lukas³ and Michel De Bandt⁴, ¹RHEUMATOLOGY, CHU Fort de France, 97261, Martinique, ²Immuno-Rhumatologie, CHU Lapeyronie, University of Montpellier, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology department, CHU Fort de France, Fort de France, France
Background/Purpose: Early seronegative rheumatoid arthritis (RA) is a separate entity. Less is known about its initial clinical presentation and outcome due to the difficulty in…
Abstract Number: 1439 • 2016 ACR/ARHP Annual Meeting
The EP4 Receptor Antagonist CR6086 Is More Effective Than Classical NSAID and DMARD Treatment in a Murine Model of Arthritis and in Human RA Synovial Explants
Marije I. Koenders¹, Monique M. Helsen¹, Birgitte Walgreen¹, Wim B. van den Berg¹, Gianfranco Caselli², Ornella Letari² and Peter M. van der Kraan¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Rottapharm Biotech, Monza, Italy
Background/Purpose: CR6086 is a novel small molecule acting as a potent and selective antagonist of the prostaglandin E2 (PGE2) receptor EP4 subtype (EP4 receptor). Recent…
Abstract Number: 2469 • 2016 ACR/ARHP Annual Meeting
How Rheumatoid Arthritis Patients and Rheumatologists Communicate during Clinic Visits When a New DMARD Is Prescribed
Lorie L. Geryk¹, Susan J. Blalock², Courtney A. Roberts², Beth L. Jonas³ and Delesha M. Carpenter⁴, ¹Division of Pharmaceutical Outcomes and Policy, University of North Carolina, Chapel Hill, NC, ²Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, ³Thurston Arthritis Research Ct, University of North Carolina Thruston Arthritis Research Center, Chapel Hill, NC, ⁴Division of Pharmaceutical Outcomes and Policy, University of North Carolina, Asheville, NC
Background/Purpose: This observational study includes data from clinic visits of 38 RA patients (3 rheumatologists) that occurred in a southeastern state from May 2014 to…
Abstract Number: 707 • 2015 ACR/ARHP Annual Meeting
Change of Enthesial Involvement Under Treatment Was Independent from the Therapeutic Strategy in Patients with Axial Spondyloarthritis within the Scqm Cohort
Ruediger Mueller¹, Toni Kaegi², Nicole Graf³, Johannes von Kempis⁴ and J.J. Luime⁵, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Kantonsspital St. Gallen, St. Gallen, Switzerland, ³graf biostatistics, Winterthur, Switzerland, ⁴Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁵Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands
Background/Purpose: Enthesitis is one of the potential extra-axial manifestations found in patients with spondyloarthritis (SpA). Enthesitis can be quantified using the MASES (Maastrich Ankylosing Spondylitis…
Abstract Number: 1932 • 2015 ACR/ARHP Annual Meeting
IL-17A-Low CCR6+ Th Cell Populations of Patients with Rheumatoid Arthritis Are Pathogenic, Multidrug Resistant and Associated with DMARD and Glucocorticoid Treatment Response
Jan Piet van Hamburg¹, Sandra M.J. Paulissen², Nadine Davelaar¹, Mieke Hazes³ and Erik Lubberts¹, ¹Rheumatology and Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, ²Room Nb-84, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, ³Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
Background/Purpose: CCR6+ T-helper (Th) cells and their pro-inflammatory cytokines including IL-17A are implicated in the pathogenesis of rheumatoid arthritis (RA). However, within the CCR6+ Th…
Abstract Number: 2837 • 2015 ACR/ARHP Annual Meeting
Sulfasalazine Comedication: A Predictor of Reduced Long-Term Anti-TNF Switch in Ankylosing Spondylitis
Andrea Y. Shimabuco, Celio R. Gonçalves, Julio C. B. Moraes, Mariana G Waisberg, Percival D Sampaio-Barros, Cláudia Goldenstein-Schainberg, Eloisa Bonfá and Carla G.S. Saad, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Anti-TNF agents are efficacious in the treatment of ankylosing spondylitis (AS). The switch to another TNF blockage can be an alternative in cases of…
Abstract Number: 942 • 2015 ACR/ARHP Annual Meeting
Update in the Management of Biologic Response Modifiers and Disease-Modifying Antirheumatic Drugs Following Coccidioidomycosis
Usman Ajaz¹, Neil M. Ampel², Varun Bhalla³, Jeffrey R. Lisse⁴ and Dominick Sudano⁵, ¹Department of Medicine, University of Arizona, Tucson, AZ, ²Department of Infectious Disease, Southern AZ VA Medical Center, Tucson, AZ, ³University of Arizona, Tucson, AZ, ⁴Arizona Arthritis Center, University of Arizona, Tucson, AZ, ⁵Rheumatology, University of Arizona, Tucson, AZ
Background/Purpose: In the Southwestern United States, Coccidioidomycosis (cocci) or Valley fever is an endemic fungal infection. It typically presents as a self-limited pulmonary illness. Patients…
Abstract Number: 2051 • 2015 ACR/ARHP Annual Meeting
Risk for Lower Intestinal Perforations in RA Patients Treated with Tocilizumab in Comparison to Treatment with TNF Inhibitors, Rituximab, Abatacept or Conventional Synthetic Dmards
Anja Strangfeld¹, Adrian Richter², Peter Herzer³, Karin Rockwitz⁴, Winfried Demary⁵, Martin Aringer⁶, Angela Zink⁷ and Joachim Listing⁸, ¹Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Rheumatologist, Scientific Advisory Board, München, Germany, ⁴Rheumatologic Practice, Goslar, Germany, ⁵Rheumatologist, Hildesheim, Germany, ⁶Rheumatology, Medicine III, University Clinical Center, Technical University Dresden, Dresden, Germany, ⁷Epidemiologie, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ⁸Epidemiology, DRFZ, Berlin, Germany
Background/Purpose: Interleukin-6 has a direct protective effect on intestinal cells. Although several cases of lower intestinal perforations (LIP) were reported in clinical trials of tocilizumab…
Abstract Number: 3102 • 2015 ACR/ARHP Annual Meeting
Increasing Circulating Adiponectin after DMARD Initiation Is Associated with Radiographic Progression in Early Aggressive RA, Regardless of Treatment Strategy
Jon T. Giles¹, S. Louis Bridges Jr.², James R. O'Dell³, Stacey Cofield⁴, George Howard⁵, Jeffrey R. Curtis⁶ and Larry W. Moreland⁷, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴School of Public Health, University of Alabama at Birmingham, Birmingham, AL, ⁵Biostatistics, The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, ⁷Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Higher levels of circulating adiponectin have been linked to radiographic progression in RA in observational studies, but never studied in the context of early…
Abstract Number: 959 • 2015 ACR/ARHP Annual Meeting
Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study
Yukiko Kimura¹, Timothy Beukelman², Esi Morgan-DeWitt³, Kelly L. Mieszkalski⁴, Thomas Brent Graham⁵, Maria F. Ibarra⁶, Norman Ilowite⁷, Marisa S. Klein-Gitelman⁸, Karen Onel⁹, Sampath Prahalad¹⁰, Marilynn G. Punaro¹¹, Sarah Ringold¹², Dana Toib¹³, Heather Van Mater¹⁴, Pamela F. Weiss¹⁵, Laura Schanberg¹⁶ and the CARRA Registry Investigators, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, Duke University Medical Center, Durham, NC, ⁵Pediatric Rheumatology, Vanderbilt Children's Hospital, Nashville, TN, ⁶Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁷Division of Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁸Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁹Pediatric Rheumatology, Univ of Chicago, Chicago, IL, ¹⁰Rheumatology, Emory University, Atlanta, GA, ¹¹Texas Scottish Rite Hospital, Dallas, TX, ¹²Pediatrics, Seattle Children's Hospital, Seattle, WA, ¹³Pediatric Rheumnatology, St. Christopher's Hospital for Children, Philadelphia, PA, ¹⁴Duke Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ¹⁵Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁶Duke University, Durham, NC
Background/Purpose: Systemic JIA (sJIA) in usual practice is commonly treated with several agents, including glucocorticoids (GC), methotrexate (MTX) and biologic agents, most commonly IL1 or…
Abstract Number: 2143 • 2015 ACR/ARHP Annual Meeting
A Safety Analysis of Tofacitinib 5mg Twice Daily Administered As Monotherapy or in Combination with Background Conventional Synthetic Dmards in a Phase 3 Rheumatoid Arthritis Population
Alan J Kivitz¹, Boulos Haraoui², Jeffrey Kaine³, Vanessa Castellano⁴, Eustratios Bananis⁴, Carol A Connell⁵, Elaine Hoffman⁵ and Liza Takiya⁶, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ³Sarasota Arthritis Research Center, Sarasota, FL, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In Phase 3 (P3) studies, tofacitinib demonstrated safety and efficacy…
Abstract Number: 3196 • 2015 ACR/ARHP Annual Meeting
Predictive Biomarkers for Response or Non-Response to MTX Monotherapy in Early RA
Karen Hambardzumyan¹, Rebecca J. Bolce², Saedis Saevarsdottir³, Kristina Forslind^4,5, Johan A Karlsson⁶ and Ronald F. van Vollenhoven¹, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, ⁴Departments of Rheumatology, Helsingborgs Hospital and University of Lund, Helsingborg and Lund, Sweden, ⁵Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: In early rheumatoid arthritis (eRA), a clinically significant proportion of patients may respond to first-line treatment with methotrexate (MTX). A priori identification of patients…
Abstract Number: 970 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Sarilumab in Combination with Csdmards in Patients with Active Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant of Anti–TNF-Î± Therapy: Results from a Phase 3 Study
Roy Fleischmann¹, Geraldo Castelar-Pinheiro², Jan Brzezicki³, Pawel Hrycaj⁴, Yong Lin⁵, Janet van Adelsberg⁶, Neil Graham⁷, Hubert van Hoogstraten⁵, Deborah Bauer⁵ and Gerd Burmester⁸, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Discipline of Rheumatology, Rio de Janeiro State University, Rio de Janeiro, Brazil, ³Centrum Kliniczno-Badawcze, Elblag, Poland, ⁴Poznan University of Medical Sciences, Poznan, Poland, ⁵Sanofi, Bridgewater, NJ, ⁶Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁷Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁸Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The investigational agent sarilumab is a human mAb directed against the IL-6 receptor. The phase 3 MOBILITY study (NCT01061736) evaluated the efficacy and safety…
Abstract Number: 2147 • 2015 ACR/ARHP Annual Meeting
The Effect of Sulfasalazine and Methotrexate on the Immunogenicity of Infliximab and Adalimumab in Patients with Spondyloarthritis
Ana Martínez¹, Chamaida Plasencia-Rodriguez², Dora Pascual-Salcedo³, Eva L. Kneepkens⁴, Gertjan Wolbink⁵, Alejandro Villalba⁶, Teresa Jurado¹, Diana Peiteado⁶, Laura Nuño⁶, Andrea Jochems¹ and Alejandro Balsa⁶, ¹Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ²Rheumatology Department, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ³Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ⁴Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain
Background/Purpose: Classic DMARDs are not routinely prescribed for axial spondyloarthritis (SpA). Recent studies have found that concomitant therapy with methotrexate (MTX) reduced immunogenicity of TNF…
Abstract Number: 3197 • 2015 ACR/ARHP Annual Meeting
Clinical Practice Experience in Rheumatoid Arthritis Patients Treated with Triple Therapy and Methotrexate-Tumor Necrosis Factor Inhibition Differs from That of Randomized Controlled Trials
Daniel Erhardt¹, Brian Sauer², Chia-Chen Teng³, Ted R. Mikuls⁴, Jeffrey R. Curtis⁵, Derek Tang⁶, Bradley S. Stolshek⁶ and Grant W. Cannon¹, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Recently published randomized controlled trials (RCTs) have demonstrated similar outcomes in rheumatoid arthritis (RA) patients treated with triple therapy [methotrexate (MTX), sulfasalazine (SUL) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.